This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mori, Y. Articles by Momma, K. Search for Related Content PubMed PubMed Citation Articles by Mori, Y. Articles by Momma, K.

CLINICAL STUDIES: PEDIATRIC CARDIOLOGY

Long-term effect of angiotensin-converting enzyme inhibitor in volume overloaded heart during growth: a controlled pilot study

^a Department of Pediatric Cardiology, The Heart Institute of Japan, Tokyo Women’s Medical University, Tokyo, Japan

Manuscript received March 24, 1998; revised manuscript received December 30, 1999, accepted February 28, 2000.

Reprint requests and correspondence: Dr. Yoshiki Mori, Department of Pediatric Cardiology, The Heart Institute of Japan, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinju-ku, Tokyo, Japan, 162-8666
moriy{at}d7.dion.ne.jp

OBJECTIVES

This study examined whether long-term therapy with an angiotensin-converting enzyme (ACE) inhibitor reduces excessive increases in left ventricular (LV) mass as well as volume in growing children with aortic regurgitation or mitral regurgitation.

BACKGROUND

The ACE inhibitor reduces volume overload and LV hypertrophy in adults with aortic or mitral regurgitation.

METHODS

This study included 24 patients whose ages ranged from 0.3 to 16 years at entry to the study. On echocardiography, we measured LV size, systolic function and mass. After obtaining baseline data, patients were allocated into two groups. Twelve patients were given an ACE inhibitor (ACE inhibitor group), and 12 patients were not (control group). Echo parameters were again assessed after an average 3.4 years of follow-up.

RESULTS

Left ventricular parameters at baseline in the two groups were similar. The Z value of LV end-diastolic dimensions decreased from +0.82 ± 0.55 to +0.57 ± 0.58 in the ACE inhibitor group, whereas it increased from +0.73 ± 0.85 to +1.14 ± 1.04 in the control group (mean change –0.25 ± 0.33 for the ACE inhibitor group vs. +0.42 ± 0.48 for the control group, p = 0.0007). The mass normalized to growth also reduced from 221 ± 93% to 149 ± 44% of normal in the ACE inhibitor group and increased from 167 ± 46% to 204 ± 59% of normal in the control group (mean change –72 ± 89% of normal for the ACE inhibitor group vs. +37 ± 35% of normal for the control group, p = 0.0007).

CONCLUSIONS

Long-term treatment with ACE inhibitors is effective in reducing not only LV volume overload but also LV hypertrophy in the hearts of growing children with LV volume overload.

Abbreviations and Acronyms   ACE = angiotensin-converting enzyme   ANOVA = analysis of variance   AR = aortic regurgitation   LV = left ventricular   MR = mitral regurgitation

This article has been cited by other articles:

				S. Mital, W. K. Chung, S. D. Colan, L. A. Sleeper, C. Manlhiot, C. B. Arrington, J. F. Cnota, E. M. Graham, M. E. Mitchell, E. Goldmuntz, et al. Renin-Angiotensin-Aldosterone Genotype Influences Ventricular Remodeling in Infants With Single Ventricle Circulation, May 31, 2011; 123(21): 2353 - 2362. [Abstract] [Full Text] [PDF]

				L. J. Burchill, H. J. Ross, and R. M. Wald Letter by Burchill et al Regarding Article, "Enalapril in Infants With Single Ventricle: Results of a Multicenter Randomized Trial" Circulation, March 15, 2011; 123(10): e373 - e373. [Full Text] [PDF]

				D. T. Hsu, V. Zak, L. Mahony, L. A. Sleeper, A. M. Atz, J. C. Levine, P. C. Barker, C. Ravishankar, B. W. McCrindle, R. V. Williams, et al. Enalapril in Infants With Single Ventricle: Results of a Multicenter Randomized Trial Circulation, July 27, 2010; 122(4): 333 - 340. [Abstract] [Full Text] [PDF]

				S. Fava, J. Azzopardi, S. Ellard, and A. T. Hattersley ACE Gene Polymorphism as a Prognostic Indicator in Patients With Type 2 Diabetes and Established Renal Disease Diabetes Care, December 1, 2001; 24(12): 2115 - 2120. [Abstract] [Full Text] [PDF]